Brief: Tectonic Therapeutic Completes Enrollment In Tx45 Apex Phase 2 Clinical Trial In Ph-Hfpef Patients
10/06/2026 21:51
BRIEF-Tectonic Therapeutic Completes Enrollment In Tx45 Apex Phase 2 Clinical Trial In Ph-Hfpef Patients June 10 (Reuters) - Tectonic Therapeutic Inc TECX.O:
TECTONIC THERAPEUTIC COMPLETES ENROLLMENT IN TX45 APEX PHASE 2 CLINICAL TRIAL IN PH-HFPEF PATIENTS
TECTONIC THERAPEUTIC - TX45 APEX PHASE 2 TOPLINE RESULTS EXPECTED IN EARLY Q1 2027
Source text: ID:nGNX2mmGkY
Further company coverage: TECX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tectonic Therapeutic
See all newsTectonic Therapeutic Inc reports results for the quarter ended June 30 - Earnings Summary
Tectonic Therapeutic Q2 net loss widens on higher costs
Tectonic Therapeutic Inc expected to post a loss of $1.35 a share - Earnings Preview
Brief: Tectonic Therapeutic Completes Enrollment In Tx45 Apex Phase 2 Clinical Trial In Ph-Hfpef Patients
Tectonic Therapeutic Q1 net loss widens on higher R&D costs